12,372 trials
Acute Coronary Syndrome
Primary: Number of Participants With First Occurrence of Any Component of Composite MACE (CV Death, MI, or Stroke) — 439; 472 Participants — p=0.121
Group B Strep Infection
Primary: GBS Culture Result (Positive Versus Negative) — 3; 6; 18; 19 Participants
Dry Eye Disease
Primary: Change in EDS (VAS) From Baseline to Day 85 — -18.0; -19.4 mm — p=0.5019
Warts, Genital · Neoplasms, Anal
Primary: Combined Incidence of Human Papillomavirus (HPV) 6/11/16/18-related Anogenital Persistent Infection — 0.2; 2.2 Cases per 100 Person-years — p=<0.001
Cardiac Disease
Primary: mPAP-to-MAP Ratio — 0.394; 0.385; 0.42; 0.40 ratio of mPAP-to-MAP — p=0.53
Atopic Dermatitis
Primary: Number of Participants With Treatment-Emergent Adverse Events — 205; 223; 14; 17 Participants
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16 — 28.7; 45.3; 47.8 percentage of…
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline in Lumbar Spine BMD at Month 12 — 5.63; 5.30 %Change of BMD
Myocardial Infarction
Primary: Composite of Time to First Heart Failure Hospitalisation or All-cause Mortality — 6.58; 5.85 Pt with events/100 pt-years at risk — p=0.2061
Small Cell Lung Carcinoma Extensive Disease
Primary: Number of Patients With Adverse Events (AEs) Grade ≥ 3 — 77; 24 Participants
Immunization; Infection
Primary: Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants…
Tetanus · Diphtheria · Pertussis
Primary: Antibody Prevalence Rate Against Anti-PRP With 1 μg/mL or Higher, Diphtheria Toxin, Pertussis, Tetanus Toxin, and Polio Virus, Defined as the Percentage of Participants…
Coronavirus Disease 2019 (COVID-19)
Primary: Number of Participants With COVID-19 Progression to a More Severe Form — 59; 89 Participants — p=0.0088
Mitral Valve Insufficiency · Left Ventricular Systolic Dysfunction
Primary: Change of EROA — 0.03; -0.05 square cm — p=<0.001
Primary IgA Nephropathy
Primary: Ratio of Urine Protein to Creatine Ratio (UPCR) at 9 Months Compared to Baseline — 0.67; 0.69 ratio